Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
Unusual Whales
The ongoing study of 200 patients has shown a low early termination rate of 4.5%, indicating that both the Halneuron® treatment and the placebo have been well tolerated by participants.
